natgillin/translations-raw huggingface dataset:
MT-45 er ikke på listen over stoffer, som ifølge De Forenede Nationers enkeltkonvention af 1961 angående narkotiske midler eller De Forenede Nationers konvention af 1971 om psykotrope stoffer skal underkastes kontrol.
Currently available information suggests that MT-45 has not been widely used.
MT-45 har ikke nogen etableret eller anerkendt anvendelse som humanmedicinsk lægemiddel eller veterinærlægemiddel i Unionen.
The substance appears to be mostly used in the home environment either by users willing to try a new substance or by opioid dependent users with no access to heroin or any other opioid.
Risikovurderingsrapporten viser, at der kun foreligger begrænset videnskabelig dokumentation om MT-45, og det påpeges, at der er behov for yderligere forskning for at fastslå, hvilke sundhedsrisici og sociale risici der er forbundet med stoffet.
Users may combine MT-45 with other psychoactive substances.
Med det materiale og de oplysninger, der foreligger i øjeblikket, er der dog et tilstrækkeligt grundlag til at lade MT-45 underkaste kontrolforanstaltninger i hele Unionen.
There is no information on the social risks that may be related to MT-45.
Eftersom stoffet kan være sundhedsskadeligt — hvilket er dokumenteret ved, at det er påvist i forbindelse med flere dødsfald — og eftersom stoffet ikke har nogen medicinsk værdi, bør MT-45 underkastes kontrolforanstaltninger.
There is no evidence of involvement of organised crime in the manufacture, distribution, trafficking and supply of MT-45 in the Union.
Eftersom der er én medlemsstat, der fører kontrol med MT-45 efter national lovgivning i overensstemmelse med forpligtelserne i henhold til De Forenede Nationers enkeltkonvention af 1961 angående narkotiske midler og De Forenede Nationers konvention af 1971 om psykotrope stoffer, og der er syv medlemsstater, der benytter andre lovgivningsmæssige foranstaltninger til at føre kontrol med det, vil indførelsen af kontrolforanstaltninger i hele Unionen kunne bidrage til at undgå problemer med grænseoverskridende retshåndhævelse og retligt samarbejde og til at beskytte mod de risici, som tilgængelighed og brug af stoffet kan indebære.
The chemical precursors and the synthetic routes used to manufacture the MT-45 detected in Member States are unknown.
Afgørelse 2005/387/RIA tillægger Rådet gennemførelsesbeføjelser for at kunne reagere hurtigt og på grundlag af ekspertise på EU-plan på fremkomsten af nye psykoaktive stoffer, som medlemsstaterne har påvist og indberettet, ved at underkaste disse stoffer kontrolforanstaltninger i hele Unionen.
MT-45 is not listed for control under the 1961 United Nations Single Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances.
Da betingelserne og proceduren for at udløse udøvelsen af sådanne gennemførelsesbeføjelser er opfyldt, bør der vedtages en gennemførelsesafgørelse for at underkaste 4,4′-DMAR og MT-45 kontrol i hele Unionen.
MT-45 has no established or acknowledged human or veterinary medical use in the Union.
Afgørelse 2005/387/RIA er bindende for Danmark, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
The Risk Assessment Report reveals that there is limited scientific evidence available on MT-45 and points out that further research would be needed to determine the health and social risks that it poses.
Afgørelse 2005/387/RIA er bindende for Irland, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
However, the evidence and information currently available provides sufficient grounds for subjecting MT-45 to control measures across the Union.
Afgørelse 2005/387/RIA er ikke bindende for Det Forenede Kongerige, som derfor ikke deltager i vedtagelsen af denne afgørelse, som gennemfører afgørelse 2005/387/RIA, og som ikke er bindende for og ikke finder anvendelse i Det Forenede Kongerige —
As a result of the health risks that it poses, as documented by its detection in several fatalities, and of the lack of medical value of this substance, MT-45 should be subjected to control measures.
VEDTAGET DENNE AFGØRELSE:
Given that one Member State controls MT-45 under national legislation complying with the obligations under the 1961 United Nations Single Convention on Narcotic Drugs and under the 1971 United Nations Convention on Psychotropic Substances and seven Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
Artikel 1
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Følgende nye psykoaktive stoffer underkastes kontrolforanstaltninger i hele Unionen:
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 4,4′-DMAR and MT-45 under control across the Union.
ethyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amin (4,4′-DMAR)
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
yclohexyl-4-(1,2-diphenylethyl)piperazin (MT-45).
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Artikel 2
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Senest den 21. oktober 2016 træffer medlemsstaterne i overensstemmelse med deres nationale lovgivning de foranstaltninger, der er nødvendige for at underkaste de nye psykoaktive stoffer i artikel 1 kontrolforanstaltninger og strafferetlige foranstaltninger som fastsat i deres lovgivning i overensstemmelse med deres forpligtelser i henhold til De Forenede Nationers enkeltkonvention af 1961 angående narkotiske midler og/eller De Forenede Nationers konvention af 1971 om psykotrope stoffer.
HAS ADOPTED THIS DECISION:
Denne afgørelse træder i kraft dagen efter offentliggørelsen i Den Europæiske Unions Tidende.
The following new psychoactive substances shall be subjected to control measures across the Union:
Denne afgørelse anvendes i overensstemmelse med traktaterne.
ethyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR);
Udfærdiget i Luxembourg, den 8. oktober 2015.
yclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).
J. Asselborn
By 21 October 2016, Member States shall take the necessary measures, in accordance with their national law, to subject the new psychoactive substances referred to in Article 1 to control measures and criminal penalties, as provided for under their legislation complying with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs and/or under the 1971 United Nations Convention on Psychotropic Substances.
EUT L 127 af 20.5.2005, s. 32.
Article 3
4,4′-DMAR har været tilgængelig på narkotikamarkedet i Unionen i hvert fald siden december 2012 og blev indberettet til systemet for tidlig varsling i december 2012.
This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.
Ni medlemsstater har rapporteret, at stoffet er blevet fundet i beslaglæggelser, hovedsageligt som hvidt eller farvet pulver og tabletter, og i biologiske og indsamlede prøver.
This Decision shall apply in accordance with the Treaties.
Der er registreret 31 dødsfald med relation til 4,4′-DMAR i tre medlemsstater fra juni 2013 til juni 2014.
Done at Luxembourg, 8 October 2015.
I de fleste tilfælde var 4,4′-DMAR enten selve dødsårsagen eller var sammen med andre stoffer sandsynligvis medvirkende til dødsfaldet.
For the Council
Der er blevet rapporteret om i alt 28 dødsfald fra november 2013 til juli 2014 fra en medlemsstat.
The President
I de fleste tilfælde blev tilstedeværelsen af MT-45 i biologiske prøver analytisk bekræftet.
OJ L 127, 20.5.2005, p. 32.
Formand
4,4′-DMAR has been available on the drugs market in the Union since at least December 2012 and was notified to the Early Warning System in December 2012.
Rådets gennemførelsesafgørelse (EU) 2015/1874
Council Implementing Decision (EU) 2015/1874
I overensstemmelse med artikel 6 i afgørelse 2005/387/RIA udarbejdede det udvidede videnskabelige udvalg under Det Europæiske Overvågningscenter for Narkotika og Narkotikamisbrug (EMCDDA) på et særligt møde en risikovurderingsrapport om 4-methylamfetamin, som efterfølgende blev forelagt Kommissionen den 29. november 2012.
A Risk Assessment Report on 4-methylamphetamine was drawn up in accordance with Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently received by the Commission on 29 November 2012.
Den vigtigste kemiske prækursor for syntesen af 4-methylamfetamin er 4-methylbenzyl methylketon (4-methyl-BMK), der tilsyneladende kan købes på internettet, og som der ikke føres kontrol med inden for rammerne af FN's konvention af 1988 imod ulovlig handel med narkotika og psykotrope stoffer.
The main chemical precursor for the synthesis of 4-methylamphetamine is 4-methylbenzyl methyl ketone (4-methyl-BMK), which appears to be commercially available on the internet and is not controlled under the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
Visse oplysninger tyder på, at en kombination af 4-methylamfetamin med andre stoffer, herunder amfetamin og koffein, kan føre til en højere risiko for en samlet øget toksicitet.
According to the limited data sources available, the acute toxicity of 4-methylamphetamine is similar to that of other stimulants.
Der er registreret i alt 21 dødsfald i fire medlemsstater, hvor 4-methylamfetamin alene eller sammen med et eller flere andre stoffer, specielt amfetamin, er blevet påvist i obduktionsprøver.
Certain evidence suggests that a combination of 4-methylamphetamine with other substances, including amphetamine and caffeine, may result in a higher risk of overall enhanced toxicity.
Ud fra de foreliggende oplysninger kan det ikke med sikkerhed fastslås, hvilken rolle 4-methylamfetamin har spillet i disse dødsfald, men stoffet var i visse tilfælde det fremherskende og forekom i mængder svarende til dem, der i nogle tilfælde var konstateret ved dødsfald forårsaget af amfetaminindtagelse.
There have been a total of 21 fatalities registered in four Member States where 4-methylamphetamine alone, or in combination with one or more substances, especially amphetamine, has been detected in post-mortem samples.
ethylamfetamin er blevet påvist i 15 medlemsstater, mens en medlemsstat har indberettet fremstilling af stoffet på landets eget område.
While it is not possible to determine with certainty from the information available the role of 4-methylamphetamine in those fatalities, in some cases the substance was the predominant drug detected, with levels comparable to those found in certain cases of death caused by the consumption of amphetamine.
Den specifikke forekomst af 4-methylamfetamin er svær at vurdere.
ethylamphetamine has been detected in 15 Member States, while one Member State has reported the manufacture of the substance on its territory.
ethylamfetamin er ikke i øjeblikket under vurdering og er ikke vurderet i FN-regi.
ethylamphetamine has no known, established or acknowledged medical value or use in the Union and there is no marketing authorisation for the substance in the Union.
Risikovurderingsrapporten viser, at der kun foreligger begrænset dokumentation om karakteristika og risici for 4-methylamfetamin og påpeger, at der er behov for yderligere undersøgelser om de generelle sundhedsrisici og sociale risici, der er forbundet med stoffet.
Apart from its use as an analytical reference standard and in scientific research, there is no indication that it may be used for any other legitimate purpose.
De foreliggende oplysninger begrunder dog i tilstrækkeligt omfang, at 4-methylamfetamin underkastes kontrolforanstaltninger i Unionen.
ethylamphetamine is not currently under assessment and has not been under assessment by the United Nations' system.
Kontrolforanstaltninger i hele Unionen kan også bidrage til at forhindre, at 4-methylamfetamin udvikler sig til at blive et alternativ til amfetamin på markederne for ulovlige stoffer.
Two other Member States apply the generic definition of phenethylamine in their national legislation to the substance, while one Member State controls it under its medicines legislation.
Denne afgørelse erstatter Rådets afgørelse 2013/129/EU [2], som blev annulleret af Den Europæiske Unions Domstol (»Domstolen«) ved dom af 16. april 2015 i sag C-317/13 [3].
As a result of the health risks it poses, as documented by its detection in several reported fatalities, especially when used in combination with other substances, of its strong resemblance in terms of appearance and effects with amphetamine, of the fact that users may unknowingly consume the substance, and of its limited medical value or use, 4-methylamphetamine should be subjected to control measures across the Union.
I denne dom opretholdt Domstolen virkningerne af afgørelse 2013/129/EU, indtil en ny lovgivning træder i kraft som erstatning herfor.
Given that 10 Member States already control 4-methylamphetamine, subjecting it to control measures across the Union may help avoid problems in cross-border law enforcement and judicial cooperation.
Derfor ophører afgørelse 2013/129/EU med at have virkning fra datoen for denne afgørelses ikrafttræden.
Union-wide control measures may also help prevent 4-methylamphetamine developing as an alternative to amphetamine in the illicit drug markets.
Med henblik på at sikre kontinuiteten af kontrolforanstaltninger i hele Unionen med hensyn til 4-methylamfetamin bør denne afgørelse ikke berøre medlemsstaternes forpligtelser med hensyn til fristen for at underkaste nye psykoaktive stoffer kontrolforanstaltninger og strafferetlige sanktioner i deres nationale lovgivning som fastsat i artikel 2 i afgørelse 2013/129/EU.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Afgørelse 2005/387/RIA er bindende for Danmark, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 4-methylamphetamine under control across the Union.
Afgørelse 2005/387/RIA er bindende for Irland, som derfor deltager i vedtagelsen og anvendelsen af denne afgørelse, der gennemfører afgørelse 2005/387/RIA.
This Decision replaces Council Decision 2013/129/EU [2] which was annulled by the Court of Justice of the European Union (‘the Court’) by its judgment of 16 April 2015 in Case C-317/13 [3].
Afgørelse 2005/387/RIA er ikke bindende for Det Forenede Kongerige, som derfor ikke deltager i vedtagelsen af denne afgørelse, som gennemfører afgørelse 2005/387/RIA, og som ikke er bindende for og ikke finder anvendelse i Det Forenede Kongerige —
In that judgment, the Court maintained the effects of Decision 2013/129/EU until the entry into force of new acts intended to replace it.
VEDTAGET DENNE AFGØRELSE:
Therefore, as of the day of entry into force of this Decision, Decision 2013/129/EU ceases to produce effects.
Artikel 1
In order to ensure the continuity of control measures across the Union with regard to 4-methylamphetamine, this Decision should be without prejudice to the obligations of the Member States relating to the time limit for subjecting that new psychoactive substance to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2013/129/EU.
Det nye psykoaktive stof 4-methylamfetamin underkastes kontrolforanstaltninger i hele Unionen.
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Artikel 2
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Afgørelse 2013/129/EU ophører med at have virkning fra datoen for nærværende afgørelses ikrafttræden, uden at dette berører medlemsstaternes forpligtelser med hensyn til fristen for at underkaste 4-methylamfetamin kontrolforanstaltninger og strafferetlige sanktioner i deres nationale lovgivning som fastsat i artikel 2 i afgørelse 2013/129/EU.
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Denne afgørelse træder i kraft dagen efter offentliggørelsen i Den Europæiske Unions Tidende.
Article 1
Denne afgørelse anvendes i overensstemmelse med traktaterne.
The new psychoactive substance 4-methylamphetamine shall be subjected to control measures across the Union.
Udfærdiget i Luxembourg, den 8. oktober 2015.
Article 2
På Rådets vegne
Decision 2013/129/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-methylamphetamine to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2013/129/EU.
J. Asselborn
Article 3
EUT L 127 af 20.5.2005, s. 32.
This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.
Rådets gennemførelsesafgørelse 2013/129/EU af 7. marts 2013 om at underkaste 4-methylamfetamin kontrolforanstaltninger (EUT L 72 af 15.3.2013, s. 11).
This Decision shall apply in accordance with the Treaties.
Domstolens dom af 16.4.2015, Parlamentet mod Rådet, C-317/13, ECLI:EU:C:2015:223.
Done at Luxembourg, 8 October 2015.
Otte medlemsstater fører kontrol med stoffet under lovgivning om narkotikakontrol i overensstemmelse med deres forpligtelser i henhold til FN-konventionen af 1971 om psykotrope stoffer.
For the Council
To andre medlemsstater anvender den generiske definition af phenethylamin i deres nationale lovgivning om stoffet, mens en medlemsstat fører kontrol med det under sin lægemiddellovgivning.
The President
Ifølge de begrænsede tilgængelige datakilder svarer den akutte toksicitet for 4-methylamfetamin til den, man finder hos andre stimulerende stoffer.
OJ L 127, 20.5.2005, p. 32.
Ifølge de foreliggende oplysninger lader det til, at 4-methylamfetamin produceres og distribueres af de samme grupper inden for den organiserede kriminalitet, som også er involveret i fremstilling og salg af stoffet amfetamin.
Council Decision 2013/129/EU of 7 March 2013 on subjecting 4-methylamphetamine to control measures (OJ L 72, 15.3.2013, p. 11).
På grund af de helbredsrisici, stoffet frembyder som påvist i forbindelse med flere rapporterede dødsfald, navnlig når det anvendes sammen med andre stoffer, det faktum, at det både med hensyn til, hvordan det ser ud og virker, minder meget om amfetamin, det faktum, at brugerne uvidende kan komme til at indtage dette stof, samt dets begrænsede medicinske værdi eller anvendelse bør 4-methylamfetamin underkastes kontrolforanstaltninger i hele Unionen.
Judgment of the Court of Justice of 16 April 2015, Parliament v Council, C-317/13, ECLI:EU:C:2015:223.
Formand
Eight Member States control the substance under drug control legislation by virtue of their obligations under the 1971 United Nations Convention on Psychotropic Substances.
Rådets gennemførelsesafgørelse (EU) 2015/1875
Council Implementing Decision (EU) 2015/1875
om at underkaste 4-iod-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamin (25I-NBOMe), 3,4-dichlor-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamid (AH-7921), 3,4-methylendioxypyrovaleron (MDPV) og 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanon (methoxetamin) kontrolforanstaltninger
on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures
I overensstemmelse med afgørelse 2005/387/RIA udarbejdede det udvidede videnskabelige udvalg under Det Europæiske Overvågningscenter for Narkotika og Narkotikamisbrug (EMCDDA) på et særligt møde risikovurderingsrapporter om de nye psykoaktive stoffer 4-iod-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamin (25I-NBOMe), 3,4-dichlor-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamid (AH-7921), 3,4-methylendioxypyrovaleron (MDPV) og 2-(3-methoxyphenyl)2-(ethylamino)cyclohexanon (methoxetamin), som efterfølgende blev forelagt Kommissionen og Rådet den 23. april 2014.
Risk Assessment Reports on the new psychoactive substances 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) were drawn up in accordance with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and were subsequently submitted to the Commission and to the Council on 23 April 2014.
NBOMe, AH-7921, MDPV og methoxetamin var ikke blevet vurderet i FN-regi, da der blev anmodet om en risikovurdering på EU-plan, men de blev i juni 2014 evalueret af Verdenssundhedsorganisationens Ekspertudvalg vedrørende Medicinafhængighed.
NBOMe, AH-7921, MDPV and methoxetamine had not been under assessment at the United Nations' level by the time the risk assessment was requested at Union level, but they were evaluated in June 2014 by the Expert Committee on Drug Dependence of the World Health Organization.
NBOMe, AH-7921, MDPV og methoxetamin har ingen dokumenterede eller anerkendte human- eller veterinærmedicinske anvendelser.
NBOMe, AH-7921, MDPV and methoxetamine have no established or acknowledged human or veterinary medical use.
Bortset fra disse stoffers anvendelse som referencematerialer ved analyse og til videnskabelig forskning i deres kemi, farmakologi og toksikologi som følge af deres opdukken på narkotikamarkedet — og for 25I-NBOMe's vedkommende tillige inden for neurokemi — har de så vidt vides ingen andre anvendelser.
Apart from their use in analytical reference materials, in scientific research investigating their chemistry, pharmacology and toxicology as a result of their emergence on the drug market and, in the case of 25I-NBOMe, also in the field of neurochemistry, there is no indication that they are being used for other purposes.
NBOMe er et kraftigt virkende syntetisk derivat af 2,5-dimethoxy-4-iodophenethylamin (2C-I), der er et klassisk serotonergt hallucinogen, som blev risikovurderet og underkastet kontrolforanstaltninger og strafferetlige sanktioner på EU-plan fra 2003 ved afgørelse 2003/847/RIA [2].
NBOMe is a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen, which was subject to risk assessment and to control measures and criminal sanctions at Union level from 2003 by virtue of Council Decision 2003/847/JHA [2].